DR. CAN ILYAS MD NPI 1770625410

NPI Information

  • NPI: 1770625410
  • Provider Name: DR. CAN ILYAS, MD
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 2 INDEPENDENCE DR
    KENNEBUNK, ME
    ZIP 04043
  • Phone: (207) 303-3300

Map and Directions

Get Directions

NPI Details

DR. Can Ilyas, MD is a hematology and oncology internal medicine in Kennebunk, ME with 32 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Can Ilyas, MD NPI is 1770625410. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

2 INDEPENDENCE DR
KENNEBUNK, ME
ZIP 04043-078
Phone: (207) 303-3300
Fax: (207) 250-2144

The NPI 1770625410 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, aprepitant, 1 mg (HCPCS:J0185)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
  • Ferritin (blood protein) level (HCPCS:82728)
  • Iron level (HCPCS:83540)
  • Iron binding capacity (HCPCS:83550)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
  • Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
  • Unclassified drugs (HCPCS:J3490)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Psa (prostate specific antigen) measurement, total (HCPCS:84153)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
  • Folic acid level, serum (HCPCS:82746)
  • Magnesium level (HCPCS:83735)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Urinalysis, manual test (HCPCS:81002)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Thyroxine (thyroid chemical), free (HCPCS:84439)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Administration of influenza virus vaccine (HCPCS:G0008)
  • Influenza vaccine split virus, preservative free (HCPCS:90662)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
  • Vitamin d-3 level (HCPCS:82306)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
  • Red blood count automated, with additional calculations (HCPCS:85046)
  • Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
  • Injection of drug or substance into vein (HCPCS:96374)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
  • Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Beta-2 microglobulin (protein) level (HCPCS:82232)

The enumeration date for this NPI number is 2/12/2007 and was last updated on 2/19/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & Oncology20015NEW HAMPSHIRENo
2207RH0003XInternal MedicineHematology & OncologyMD17729MAINEYes

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
130207924MEDICAIDMAINE
2432956599MEDICAIDNEW HAMPSHIRE

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 3/30/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.